Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced today that a poster on Tonmya (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM). The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the company will share data related to its investigational therapy as part of the scientific program.
Tonmya, recently approved as the first new treatment for fibromyalgia in more than 15 years, is the company's flagship medicine. The presentation at AAPM underscores Tonix's commitment to advancing therapies for central nervous system (CNS) conditions with high unmet medical need. The company's CNS portfolio also includes Zembrace SymTouch and Tosymra for acute migraine, as well as investigational candidates TNX-2900 for Prader-Willi syndrome and TNX-4800 for Lyme disease prophylaxis.
The data to be presented at the meeting may provide further insights into Tonmya's efficacy and safety profile, potentially influencing clinical practice and future research. Tonix is also evaluating Tonmya in Phase 2 clinical trials for major depressive disorder and acute stress disorder, expanding its therapeutic reach beyond fibromyalgia.
Tonix's immunology pipeline includes TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/kwTPM.
